The pharmaceutical industry has shifted its R&D attention from primary care to specialty care medicines. This move to develop medicines that treat smaller populations at a much higher cost has dramatically changed new product launch strategies and tactics.
This document is a presentation by Best Practices, LLC Chief Executive Officer, Chris Bogan that looks at how the specialty market requires better lifecycle planning and thought leader targeting than traditional launches.
SAMPLE KEY FINDINGS
1. The Revolution in Biologics Is Changing Required Skills to Compete in Specialty Markets
2. Segmentation & Targeting Take On Greater Nuance & Impact In The New World
3. Higher Specialty Pricing Makes Medicines Targets For Brutal Attacks, High Competition & Innovative Adaptation